Top 10 per capita output of pharmaceutical enterprises in 2014

Source: Xinkangjie / shaojianguo July 27, 2015 according to the latest report of evaluatepharma, Bayer increased 5700 employees in 2014, and Baite and Meilan increased 5000 employees respectively To a large extent, this increase in the number of employees reflects the warming pace of M & A in 2014, such as the co promotion of chairman Paul bisaro and CEO Brent Saunders, who became CEO of atvis after the acquisition of forest laboratory by atvis in 2014 As a product of the M & a boom in 2015, it has been renamed as Aerjian's atvis, with an increase of 2400 employees in 2014 From the perspective of organic growth, there are also some companies in the top 10 of medium-sized pharmaceutical companies Novo Nordisk ranked fourth in the list of staff increase in 2014 The company increased 3014 employees in 2014, with a total number of 41450 The remaining five companies are biotechnology companies, namely, Sergio, Gilead science, BGI, Zaiyuan and alexion pharmaceutical Compared with their scale, each company has made significant organic growth However, Gilead science, ranked seventh in the ranking of staff increase in 2014, may be the company with relatively small staff increase in 2014, when the company successively launched the hepatitis C treatment drugs sofosbuvir (sovaldi) and harvoni (combination of sofibvir and ledipasvir) Although Gilead science added only 900 employees in 2014, its sales revenue soared by 126.5% to US $24.474 billion, with an overall increase As a result, Geely's CEO can see the high per capita income that other pharmaceutical companies can't match According to the annual income of US $24.474 billion, calculated by 7000 employees, Geely Tech's per capita income reached US $3.5 million in 2014, and successfully topped the top 10 per capita income in 2014 Next came the Searle gene, which is $1.26 million The top 5 companies in 2014, such as Gilead science, Sergio, shire, Baijian Aidi and Amgen, all have exceeded $1 million in per capita income In 2014, the per capita income of a strong person ranked the 10th in per capita income was only $590000 Among the large pharmaceutical companies, Pfizer is the only one in the top 10 in per capita income in 2014, ranking seventh with per capita income of 620000 US dollars But for Pfizer, epvantage points out that the sharp rise in per capita earnings can only be attributed to the decline in the number of employees, which has cut 51000 employees in the past seven years If Pfizer succeeds in winning AstraZeneca for at least $100 billion in 2014, the figure will change significantly, but Pfizer fails to achieve it under strong political pressure and public opposition Midsize pharmaceutical companies did not just significantly increase their staff in 2014 Looking back on the past 10 years, some changes deserve our attention So which company has increased the most in the past 10 years? The answer is TIWA pharmaceutical In the past 10 years, TIWA pharmaceutical has increased its staff by nearly 30000 to 43000, an increase of 67% However, as a strong player in the field of generic drugs, TIWA pharmaceutical, whose flagship drug of multiple sclerosis treatment, Copaxone, is about to face the impact of generic drugs, also began to cut staff Once TIWA is able to buy mylan for $43 billion, the company's staff will rise sharply again At the bottom of the list are the owners of the future M & A, mylan, atvis and valante Now it's up to who can stand up These companies will lay off a lot of staff after every big M & a transaction, but the number of staff is huge If you don't believe it, in other words, in the past 10 years, the number of employees in mylan has increased from 3000 to 25000, that in atvis has increased from 3850 to 216000, and that in warrand has increased from 2290 to 16800, according to epvantage Although the number of employees of large pharmaceutical companies has changed a little in the past 10 years, there are also companies that have changed a lot in terms of the increase or decrease of the number of employees Over the past decade, for example, Novartis, the Swiss pharmaceutical giant, has seen its staff increase by 64%, while Pfizer's staff decline by 32% In 2014, the number of employees of three large pharmaceutical companies also changed significantly For example, the number of employees in MSD decreased by 8% and Bristol Myers Squibb by 11% AstraZeneca, however, seems to have overcome the dilemma of substantial layoffs caused by the patent cliff of proton pump inhibitor Nexium (esomeprazole, Nexium) and lipid-lowering drug codeine (rosuvastatin, Crestor) In 2014, AstraZeneca's staff increased by 6000, or 12%, and successfully resisted Pfizer's acquisition Epvantage also pointed out that with Bristol Myers Squibb's position as a leader in the field of tumor immunotherapy, the company's recovery in growth is just around the corner.